MedTrace Logo

Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin

NCT00576784 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-12-19

No results posted yet for this study

Summary

The goal of the study is to demonstrate whether a switch from insulin therapy to an oral therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control (increase in HbA1c by more than 0.5 %) within a 6 month observation period.

Conditions

Interventions

DRUG

pioglitazone and glimepiride

switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.

Sponsors & Collaborators

  • IKFE Institute for Clinical Research and Development

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2007-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00576784 on ClinicalTrials.gov